SEGMENT REPORTING (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Segment Reporting, Other Significant Reconciling Item [Line Items]
Total revenue	$ 30,654	$ 29,511
Operating loss	(4,618)	(75)
Income before income taxes	(6,817)	(59)
Capital expenditures	210	234
Depreciation and amortization	1,374	1,265
Investments in unconsolidated affiliates	7,295		$ 7,424
Assets	350,981		244,424
Net Assets	270,638		154,364
Operating Segments | Core Companion Animal Health
Segment Reporting, Other Significant Reconciling Item [Line Items]
Total revenue	27,306	24,716
Operating loss	(4,180)	(51)
Income before income taxes	(6,379)	(35)
Capital expenditures	128	44
Depreciation and amortization	1,042	947
Investments in unconsolidated affiliates	7,295		7,424
Assets	331,932		223,980
Net Assets	255,237		137,072
Operating Segments | Other Vaccines, Pharmaceuticals and Products
Segment Reporting, Other Significant Reconciling Item [Line Items]
Total revenue	3,348	4,795
Operating loss	(438)	(24)
Income before income taxes	(438)	(24)
Capital expenditures	82	190
Depreciation and amortization	332	$ 318
Investments in unconsolidated affiliates	0		0
Assets	19,049		20,444
Net Assets	$ 15,401		$ 17,292